Solid oral forms availability in children: a cost saving investigation
- PMID: 24965935
- PMCID: PMC4243883
- DOI: 10.1111/bcp.12442
Solid oral forms availability in children: a cost saving investigation
Abstract
Aim: To assess the suitability and potential cost savings, from both the hospital and community perspective, of prescribed oral liquid medicine substitution with acceptable solid forms for children over 2 years.
Method: Oral liquid medicines dispensed from a paediatric hospital (UK) in 1 week were assessed by screening for existence of the solid form alternative and evaluating the acceptability of the available solid form, firstly related to the prescribed dose and secondly to acceptable size depending on the child's age. Costs were calculated based on providing treatment for 28 days or prescribed duration for short term treatments.
Results: Over 90% (440/476) of liquid formulations were available as a marketed solid form. Considering dosage acceptability (maximum of 10% deviation from prescribed dosage or 0% for narrow therapeutic range drugs, maximum tablet divisions into quarters) 80% of liquids could be substituted with a solid form. The main limitation for liquid substitution would be solid form size. However, two-thirds of prescribed liquids could have been substituted with a suitable solid form for dosage and size, with estimated savings being of £5K and £8K in 1 week, respectively based on hospital and community costs, corresponding to a projected annual saving of £238K and £410K (single institution).
Conclusion: Whilst not all children over 2 years will be able to swallow tablets, drug cost savings if oral liquid formulations were substituted with suitable solid dosage forms would be considerable. Given the numerous advantages of solid forms compared with liquids, this study may provide a theoretical basis for investing in supporting children to swallow tablets/capsules.
Keywords: drug formulation; oral drug delivery; paediatric; swallowing.
© 2014 The British Pharmacological Society.
Figures





Similar articles
-
Age-appropriate and acceptable paediatric dosage forms: Insights into end-user perceptions, preferences and practices from the Children's Acceptability of Oral Formulations (CALF) Study.Int J Pharm. 2016 Nov 30;514(1):296-307. doi: 10.1016/j.ijpharm.2016.07.054. Int J Pharm. 2016. PMID: 27863675
-
Register-based study showed that the age when children were prescribed antibiotic tablets and capsules instead of liquids increased from 2004 to 2016.Acta Paediatr. 2019 Apr;108(4):699-706. doi: 10.1111/apa.14550. Epub 2018 Sep 14. Acta Paediatr. 2019. PMID: 30136300
-
Acceptability of different oral formulations in infants and preschool children.Arch Dis Child. 2013 Sep;98(9):725-31. doi: 10.1136/archdischild-2012-303303. Epub 2013 Jul 13. Arch Dis Child. 2013. PMID: 23853004 Free PMC article. Clinical Trial.
-
Evidence of acceptability of oral paediatric medicines: a review.J Pharm Pharmacol. 2017 Apr;69(4):361-376. doi: 10.1111/jphp.12610. Epub 2016 Aug 14. J Pharm Pharmacol. 2017. PMID: 27524471 Review.
-
[Oral formulation of choice for children].Arch Pediatr. 2015 Aug;22(8):877-85. doi: 10.1016/j.arcped.2015.05.012. Epub 2015 Jul 2. Arch Pediatr. 2015. PMID: 26141805 Review. French.
Cited by
-
Cholera toxin B: one subunit with many pharmaceutical applications.Toxins (Basel). 2015 Mar 20;7(3):974-96. doi: 10.3390/toxins7030974. Toxins (Basel). 2015. PMID: 25802972 Free PMC article. Review.
-
Drinkable in situ-forming tough hydrogels for gastrointestinal therapeutics.Nat Mater. 2024 Sep;23(9):1292-1299. doi: 10.1038/s41563-024-01811-5. Epub 2024 Feb 27. Nat Mater. 2024. PMID: 38413810 Free PMC article.
-
Children's Preferences for Oral Dosage Forms and Their Involvement in Formulation Research via EPTRI (European Paediatric Translational Research Infrastructure).Pharmaceutics. 2021 May 15;13(5):730. doi: 10.3390/pharmaceutics13050730. Pharmaceutics. 2021. PMID: 34063499 Free PMC article.
-
Acceptability, Swallowability, Palatability, and Safety of Multiple Film-Coated Mini-Tablets in Children Aged ≥2-<7 Years: Results of an Open-Label Randomised Study.Pharmaceutics. 2023 Feb 20;15(2):701. doi: 10.3390/pharmaceutics15020701. Pharmaceutics. 2023. PMID: 36840023 Free PMC article.
-
Trends in Light and Temperature Sensitivity Recommendations among Licensed Biotechnology Drug Products.Pharm Res. 2023 Jun;40(6):1491-1505. doi: 10.1007/s11095-023-03494-0. Epub 2023 Apr 6. Pharm Res. 2023. PMID: 37022633 Free PMC article.
References
-
- Salunke S, Hempenstall J, Kendall R, Roger B, Mroz C, Nunn T, Tuleu C. European Paediatric Formulation Initiative's (EuPFI) 2nd conference commentary – Formulating better medicines for children. Int J Pharm. 2011;419:235–239. - PubMed
-
- European Medicines Agency, Committee for Medicinal Products for Human Use. 2006. Reflection paper: formulations of choice for the paediatric population; EMEA/CHMP/PEG/194810/2005.
-
- Walsh J, Mills S. Conference report: formulating better medicines for children: 4th European Paediatric Formulation Initiative conference. Ther Deliv. 2013;4:21–25. - PubMed
-
- Cram A, Breitkreutz J, Desset-Brethes S, Nunn T, Tuleu C European Paediatric Formulation I. Challenges of developing palatable oral paediatric formulations. Int J Pharm. 2009;365:1–3. - PubMed
-
- Nahata MC. Lack of pediatric drug formulations. Pediatrics. 1999;104:607–609. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources